marked.bio

anti-HER3 antibody ยท antibody

HMBD-001

2 active trials, targeting HER3. Not approved for any biomarker on marked.bio yet.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
NRG1 fusion 2 2 Phase 1/2

Sponsors

Industry sponsors leading active biomarker-selected trials of HMBD-001.

  1. Hummingbird Bioscience 1

Trials

2 of 2 trials shown

  1. A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours

    Active, not recruiting Phase 1/2 Cancer Research UK Started 2021Primary completion 2025-11 NCT05057013

    HMBD-001enzalutamide

    Participants with a confirmed existing NRG1 fusion rearrangement or HER amplification will also be considered eligible.

    NRG1 fusionBladder Cancer, Triple Negative Breast Cancer, Castration-resistant Prostate Cancer, Cervical Cancer

  2. Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation

    Active, not recruiting Phase 1 Hummingbird Bioscience Started 2023Primary completion 2031-03 NCT05919537

    HMBD-001docetaxelnab-paclitaxelgemcitabine

    Arms A, B and C: Cancer harboring an NRG1 gene fusion with EGF-like domain

    NRG1 fusionNon-Small Cell Lung Cancer, Pancreatic Cancer, Locally Advanced Solid Tumor, Metastatic Solid Tumor